Teva Pharmaceuticals
Teva Pharmaceuticals Industries Ltd., commonly known as Teva, is a global leader in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established a strong presence in over 60 countries, focusing on the development, production, and marketing of generic and specialty medicines. With a diverse portfolio that includes a wide range of therapeutic areas such as central nervous system disorders, oncology, and respiratory conditions, Teva is renowned for its commitment to accessibility and innovation. The company’s core products, including the widely used Copaxone and a robust selection of generic medications, set it apart in a competitive market. Teva's notable achievements include being one of the largest generic drug manufacturers globally, reflecting its significant market position and dedication to improving patient outcomes through affordable healthcare solutions.
DitchCarbon Score
How does Teva Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Pharmaceuticals's score of 50 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Teva Pharmaceuticals's reported carbon emissions
In 2023, Teva Pharmaceuticals reported total carbon emissions of approximately 471,063,000 kg CO2e, comprising 242,056,000 kg CO2e from Scope 1 and 229,007,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming for net-zero emissions across its operations and value chain by 2045. In the near term, Teva is targeting a 25% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2025 and a 46.2% reduction by 2030, using 2019 as the baseline year. Additionally, the company plans to reduce its absolute Scope 3 emissions by 25% by 2030, compared to 2020 levels. These initiatives reflect Teva's commitment to sustainable practices within the pharmaceutical industry, aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
